Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Fig. 1

Enrollment of diabetic patients taking metformin plus DPP-4 inhibitor versus other hypoglycemic agents. A total of 16,017 diabetic patients taking metformin plus DPP-4 inhibitor are compared with 74,863 patients prescribed other hypoglycemic agents (including sulfonylurea, alpha glucosidase inhibitor, thiazolidinedione, meglitinide, insulin, or glucagon-like peptide 1). AF atrial fibrillation, DM diabetes mellitus, DPP4i dipeptidyl peptidase-4 inhibitor, HA hypoglycemic agent

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840